Khan v. Merit Medical Systems: Supreme Court Denies AV Shunt Patent Petition
Nazir Khan petitioned the U.S. Supreme Court to review infringement claims against Merit Medical Systems over two patents covering hybrid arteriovenous shunt technology. The Court denied the petition in 244 days, ending Khan’s appellate path at the highest judicial level.
Supreme Court shuts the door on AV shunt patent infringement challenge
Nazir Khan, an individual inventor, filed a petition for certiorari with the U.S. Supreme Court on February 12, 2025, seeking review of an infringement action against Merit Medical Systems, Inc. The dispute centred on two patents — US8747344B2 and US8282591B2 — both directed to hybrid arteriovenous shunt technology used in vascular access procedures. Khan appeared to be representing himself in part, based on the docket listing him as his own plaintiff agent alongside retained counsel from Quicker Law LLC.
The Supreme Court denied the petition on October 14, 2025, closing the case after 244 days. A denial of certiorari does not constitute a ruling on the merits; it signals only that the Court declined to hear the case. The basis of termination is recorded as ‘Petition Dismissed,’ consistent with the standard procedural disposition of a cert denial. Merit Medical Systems, represented by Quicker Law LLC and Workman Nydegger, successfully defended against review.
A 244-day timeline from petition to denial is broadly consistent with the Supreme Court’s standard cert review cycle. The Court denies more than 99% of petitions received, making this outcome statistically expected rather than an exceptional rebuke. What the public record does not reveal is whether lower court rulings on validity, infringement, or claim construction drove the outcome, or whether procedural deficiencies contributed to the denial. The underlying dispute over these vascular access patents therefore concludes without Supreme Court guidance on any substantive question.
Filing to Petition Dismissed in 244 days
244 days from filing to denial — a typical cert petition timeline
Supreme Court denies cert: what the ruling means for both parties
Cert denial ends review without a merits ruling
A Supreme Court denial of certiorari is not a decision on the merits. The Court is not affirming or reversing the lower court on substance; it is simply declining to exercise its discretionary jurisdiction. The practical effect is that the most recent lower court judgment becomes final and binding. Khan exhausts his domestic appellate options at this point.
Certiorari denied — no merits adjudicationKhan’s infringement claims cannot proceed further
With the petition denied, Khan has no further avenue to pursue infringement claims in U.S. federal courts against Merit Medical for the conduct already litigated. US8747344B2 and US8282591B2 remain issued patents — the denial does not invalidate them — but the enforceability of those patents against Merit Medical in this matter is effectively concluded by the lower court outcome.
Patents intact but claim path exhaustedMerit Medical secures finality on infringement exposure
Merit Medical Systems achieves certainty: the infringement action brought by Khan is concluded with no Supreme Court intervention. The company can treat the lower court’s disposition as final. Represented by two law firms — Quicker Law LLC and Workman Nydegger — Merit Medical’s defence strategy successfully prevented any further escalation of this hybrid AV shunt patent dispute.
Infringement action finally resolvedAV shunt IP landscape: no new precedent created
Because the Supreme Court denied cert without comment, no new precedent is established for hybrid arteriovenous shunt technology or the specific claim constructions at issue. Competitors and device makers in the vascular access space face the same legal landscape as before. However, the underlying patents remain in force and could theoretically be asserted against different parties in future proceedings.
No precedential effect on AV shunt IPFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Nazir Khan | Individual | Individual inventor — holder of US8747344B2 and US8282591B2 (hybrid AV shunt)Search in Eureka ↗ |
| Defendant | Merit Medical Systems, Inc. | Company | Merit Medical Systems, Inc. — medical device manufacturer, vascular access productsSearch in Eureka ↗ |
| Plaintiff counsel | Nazir Khan | Attorney | Counsel for Nazir KhanSearch in Eureka ↗ |
| Plaintiff law firm | Quicker Law LLC | Law Firm | Representing Nazir KhanSearch in Eureka ↗ |
| Defendant counsel | David R. Todd | Attorney | Counsel for Merit Medical Systems, Inc.Search in Eureka ↗ |
| Defendant counsel | Katrina M. Quicker | Attorney | Counsel for Merit Medical Systems, Inc.Search in Eureka ↗ |
| Defendant law firm | Quicker Law LLC | Law Firm | Representing Merit Medical Systems, Inc.Search in Eureka ↗ |
| Defendant law firm | Workman Nydegger | Law Firm | Representing Merit Medical Systems, Inc.Search in Eureka ↗ |
| Presiding judge | Judge N/A | Judge | U.S. Supreme CourtSearch in Eureka ↗ |
Official order — verbatim text
The Supreme Court’s one-word disposition — ‘Petition DENIED’ — carries significant procedural weight but zero merits content. The Court exercises discretionary certiorari jurisdiction and declines the vast majority of petitions without explanation. Accordingly, this denial should not be read as endorsement of any lower court finding on infringement, validity, or claim construction of US8747344B2 or US8282591B2. For Merit Medical, the denial confers finality. For Khan, all domestic judicial avenues are now exhausted.
US8747344B2 & US8282591B2 — Hybrid Arteriovenous Shunt Technology
US8747344B2 (App. No. 13/645862) and US8282591B2 (App. No. 10/812380) both relate to hybrid arteriovenous shunt technology — devices used to create vascular access in patients, typically for haemodialysis or related procedures. The ‘hybrid’ designation typically signals an innovation combining features of both synthetic graft and native vessel approaches to improve patency or clinical performance. The two application numbers suggest a generational relationship, with the earlier application potentially establishing foundational claims that the later filing extended.
Arteriovenous access is a clinically critical — and commercially contested — area of medical device development. Major device makers including Merit Medical Systems compete in vascular access markets worth billions of dollars annually. Patents in this space often cover nuanced structural and functional distinctions in shunt geometry, material composition, or anastomosis design. An individual inventor holding two issued patents in this category represents a meaningful enforcement risk to commercial players, making the litigation history of these specific assets strategically relevant for competitors.
Should your team run an FTO against US8747344B2 and US8282591B2?
Any R&D or product team developing arteriovenous shunt devices, vascular access grafts, or related haemodialysis access products should assess freedom-to-operate against these two patents. US8747344B2 and US8282591B2 remain in force as issued patents. The Supreme Court’s cert denial does not narrow their claims or limit assertion against parties other than those involved in the concluded litigation. If your product competes in the hybrid AV shunt space, these patents warrant direct claim-mapping analysis.
PatSnap Eureka’s FTO Search Agent can ingest the independent claims of US8747344B2 and US8282591B2, map them against your product specifications, and surface prior art or design-around pathways in minutes. Eureka also tracks prosecution history and citation networks — critical context for understanding how broadly these claims have been interpreted by examiners and courts. Start an FTO analysis directly from the patent page to benchmark your exposure before product launch or next funding round.
Run a freedom-to-operate analysis on US8747344B2 to assess your product’s exposure
Run FTO in Eureka →Similar vascular device patent infringement cases at appellate level
Cases involving arteriovenous shunt and vascular access patents litigated to the U.S. Supreme Court or Federal Circuit, with comparable infringement and cert postures.
What this case signals for the vascular device IP landscape
A Supreme Court cert denial closes this chapter, but the asserted patents remain live assets. Here is what IP and R&D teams should take away.
Cert denial ≠ patent invalidity — monitor these patents for future assertions
US8747344B2 and US8282591B2 survive this litigation as issued patents. A cert denial does not affect patent validity or scope. Any company operating in the vascular access or AV shunt space should track these patents for potential future enforcement against new defendants or products.
Individual inventor enforcement at the Supreme Court level is rare and high-risk
Khan’s self-representation at the petition stage, combined with the Court’s >99% denial rate, suggests this pathway was always a long-shot. For in-house IP teams, this case reinforces that certiorari is an exceptional remedy, not a reliable appeal route for individual inventors pursuing infringement claims.
Khan v Merit — key questions answered
The denial means the Court declined to hear the case. It is not a ruling on the merits of the infringement claims over US8747344B2 or US8282591B2. The most recent lower court judgment becomes final. Khan’s domestic appellate options are exhausted, and Merit Medical achieves finality on the infringement action.
Yes. A Supreme Court cert denial has no effect on patent validity. Both patents remain issued and in force unless separately challenged through inter partes review, ex parte reexamination, or a new district court invalidity action. The denial only concludes this specific infringement proceeding.
A hybrid arteriovenous shunt combines elements of synthetic graft and native vessel vascular access, typically for haemodialysis patients. The ‘hybrid’ approach can improve patency and reduce complications. This clinical differentiation supports patentable innovation in geometry, materials, or surgical technique — making the space commercially and legally contested.
Yes. The cert denial resolves only the dispute between Khan and Merit Medical. Nothing in this disposition prevents Khan from filing new infringement actions against different defendants based on the same patents, provided the patents remain in force and the relevant statutes of limitations have not expired.
Merit Medical was represented by David R. Todd and Katrina M. Quicker of Quicker Law LLC, and by Workman Nydegger. The dual-firm representation suggests coordinated strategy combining Supreme Court procedural expertise with specialist patent litigation counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.